| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Not applicable. As a stable isotope-labeled endogenous metabolite, L-Lactic acid-13C3 does not have a pharmacological target. It is a metabolic tracer used to study lactate dehydrogenase (LDH) activity, the Cori cycle, and other metabolic pathways. Unlabeled L-Lactic acid is a key intermediate in carbohydrate metabolism, produced from pyruvate via lactate dehydrogenase.
|
|---|---|
| ln Vitro |
The labeled compound is not used for its biological activity but as an internal standard and metabolic tracer. Unlabeled L-lactic acid is an endogenous metabolite and an important substrate in energy metabolism. L-Lactic acid-13C3 is used to quantify lactate flux through metabolic pathways, including gluconeogenesis and the TCA cycle, by tracking the 13C label via mass spectrometry or NMR.
|
| ln Vivo |
No specific in vivo activity has been reported. As a metabolic tracer, L-Lactic acid-13C3 is administered intravenously or intraperitoneally to animals or humans to track lactate metabolism. It is used to study metabolic disorders such as lactic acidosis, sepsis, and cancer metabolism, as well as to quantify the contribution of lactate to gluconeogenesis under various physiological conditions.
|
| Enzyme Assay |
Not applicable. L-Lactic acid-13C3 is an internal standard and metabolic tracer, not a drug candidate. For metabolic tracer experiments, a typical protocol involves dissolving the compound in saline or PBS and administering via intravenous (i.v.) or intraperitoneal (i.p.) injection. Blood and tissue samples are collected at various time points, and metabolites are extracted for analysis by LC-MS or GC-MS. The 13C enrichment in lactate and its metabolites (e.g., glucose, alanine, pyruvate) is quantified to calculate metabolic flux.
|
| Cell Assay |
L-Lactic acid-13C3 is not used in cell-based assays as a test article. It is used as a tracer in metabolic studies. For cell culture experiments, cells are cultured in glucose-containing medium and treated with L-Lactic acid-13C3 (e.g., 1-10 mM). After 1-24 hours of incubation, cellular metabolites are extracted with 80% cold methanol. The 13C-labeled lactate, pyruvate, and TCA cycle intermediates are analyzed by LC-MS to trace carbon flux through metabolic pathways. This approach is commonly used in cancer metabolism research to study the Warburg effect.
|
| Animal Protocol |
In a typical in vivo metabolic flux study, male C57BL/6 mice (8-12 weeks old) are fasted overnight. L-Lactic acid-13C3 is dissolved in saline and administered via intraperitoneal (i.p.) injection at a dose of 0.5-2 g/kg. Blood samples are collected via tail vein at 0, 15, 30, 60, 90, and 120 minutes post-injection. Plasma is separated, and the 13C enrichment of lactate and glucose is analyzed by GC-MS. Alternatively, a primed continuous infusion (e.g., 5-10 mg/kg/min) can be used to achieve steady-state labeling for metabolic flux calculations. Tissues (liver, muscle, brain) are harvested for analysis.
|
| ADME/Pharmacokinetics |
L-Lactic acid-13C3 (molecular weight 93.06 g/mol) has the same ADME properties as unlabeled L-lactic acid. L-Lactic acid is a small, water-soluble molecule that is rapidly absorbed and distributed throughout the body. It is endogenously produced from glucose and is a key intermediate in energy metabolism. Exogenous lactate is rapidly metabolized, primarily by the liver via gluconeogenesis (Cori cycle). The plasma half-life is short (minutes). The labeled compound is used to trace these pathways.
|
| Toxicity/Toxicokinetics |
No toxicity data is reported for L-Lactic acid-13C3. Unlabeled L-lactic acid is an endogenous metabolite and is generally recognized as safe (GRAS) at physiological concentrations. High doses of exogenous lactate may cause mild acidosis, but the labeled compound is used in tracer amounts and does not cause toxicity. The compound is labeled with stable isotope 13C, which is non-radioactive and safe for research use.
|
| References |
[1]. Ana Lívia Chemeli Senedese, et al. L-lactic acid production by Lactobacillus rhamnosus ATCC 10863. ScientificWorldJournal. 2015;2015:501029.
|
| Additional Infomation |
L-Lactic acid-13C3 is a stable isotope-labeled biochemical used as a tracer for metabolic research. The molecular formula is 13C3H6O3, and the molecular weight is 93.06 g/mol. The IUPAC name is (2S)-2-hydroxy(1,2,3-13C3)propanoic acid. The compound has high isotopic purity (typically ≥99% 13C) and chemical purity (≥98%). It is soluble in water and is stored at 2-8degC or -20degC. It is not approved for clinical use.
|
| Molecular Formula |
13C3H6O3
|
|---|---|
| Molecular Weight |
93.06
|
| Exact Mass |
93.041
|
| CAS # |
87684-87-5
|
| Related CAS # |
L-Lactic acid;79-33-4;L-Lactic acid-13C3 sodium;201595-71-3
|
| PubChem CID |
16213313
|
| Appearance |
White to off-white solid powder
|
| LogP |
-0.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
6
|
| Complexity |
59.1
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[13CH3][13C@@H]([13C](=O)O)O
|
| InChi Key |
JVTAAEKCZFNVCJ-GCCOVPGMSA-N
|
| InChi Code |
InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)/t2-/m0/s1/i1+1,2+1,3+1
|
| Chemical Name |
(2S)-2-hydroxy(1,2,3-13C3)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 10.7458 mL | 53.7288 mL | 107.4576 mL | |
| 5 mM | 2.1492 mL | 10.7458 mL | 21.4915 mL | |
| 10 mM | 1.0746 mL | 5.3729 mL | 10.7458 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
